Eliquis Sprinkle is a drug owned by Bristol Myers Squibb Co. It is protected by 4 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 22, 2041. Details of Eliquis Sprinkle's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US6967208 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
Nov, 2026
(1 year, 3 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US11896586 (Pediatric) | Apixaban formulations |
May, 2041
(15 years from now) | Active |
| US11896586 | Apixaban formulations |
Nov, 2040
(15 years from now) | Active |
|
US6967208 (Pediatric) | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
May, 2027
(1 year, 9 months from now) | Active |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Eliquis Sprinkle and ongoing litigations to help you estimate the early arrival of Eliquis Sprinkle generic.
Eliquis Sprinkle's Litigations
Eliquis Sprinkle been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 13, 2015, against patent number US6967208. The petitioner Coalition for Affordable Drugs IX, LLC, challenged the validity of this patent, with Bristol-Myers Squibb Company as the respondent. Click below to track the latest information on how companies are challenging Eliquis Sprinkle's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6967208 | August, 2015 |
Terminated-Denied
(22 Feb, 2016) | Bristol-Myers Squibb Company | Coalition for Affordable Drugs IX, LLC |
FDA has granted some exclusivities to Eliquis Sprinkle. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Eliquis Sprinkle, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Eliquis Sprinkle.
Exclusivity Information
Eliquis Sprinkle holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Eliquis Sprinkle's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 17, 2028 |
| Pediatric Exclusivity(PED) | Oct 17, 2028 |
US patents provide insights into the exclusivity only within the United States, but Eliquis Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Eliquis Sprinkle's family patents as well as insights into ongoing legal events on those patents.
Eliquis Sprinkle's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Eliquis Sprinkle's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 22, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Eliquis Sprinkle Generic API suppliers:
Apixaban is the generic name for the brand Eliquis Sprinkle. 13 different companies have already filed for the generic of Eliquis Sprinkle, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Eliquis Sprinkle's generic
Alternative Brands for Eliquis Sprinkle
There are several other brand drugs using the same active ingredient (Apixaban) as Eliquis Sprinkle. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bristol Myers Squibb |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Apixaban, Eliquis Sprinkle's active ingredient. Check the complete list of approved generic manufacturers for Eliquis Sprinkle
About Eliquis Sprinkle
Eliquis Sprinkle is a drug owned by Bristol Myers Squibb Co. Eliquis Sprinkle uses Apixaban as an active ingredient. Eliquis Sprinkle was launched by Bristol in 2025.
Approval Date:
Eliquis Sprinkle was approved by FDA for market use on 17 April, 2025.
Active Ingredient:
Eliquis Sprinkle uses Apixaban as the active ingredient. Check out other Drugs and Companies using Apixaban ingredient
Dosage:
Eliquis Sprinkle is available in for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.15MG | FOR SUSPENSION | Prescription | ORAL |